ARMD1 is inherited in an autosomal dominant pattern; one copy of the associated variant is sufficient to confer susceptibility, and each child of an affected individual has a 50% chance of inheriting it. The condition is associated with variation at a specific chromosomal locus on chromosome 1q25.3-q31.1; the precise molecular mechanism contributing to macular deterioration is under investigation in available data.

Diagnosis involves comprehensive ophthalmic evaluation for macular drusen and retinal changes consistent with macular degeneration. Optical coherence tomography and fundus imaging are typically employed in clinical assessment. A family history consistent with autosomal dominant transmission may further support the clinical picture.

No treatments are listed as specifically approved for ARMD1 in this packet. Management focuses on evaluating disease progression and addressing complications as they arise. Supportive care and low-vision rehabilitation may assist individuals with functional vision impairment. Treatment approaches are individualized through ophthalmologic specialist evaluation.

Outcomes vary considerably among individuals. Geographic atrophy, when present, is associated with progressive central vision loss over time. Macular hemorrhage may indicate a more rapidly progressive course. Peripheral vision is generally preserved, and overall trajectory depends on the degree of macular involvement and other individual factors.

Age related macular degeneration 1 is part of an active area of clinical research, with numerous ongoing clinical trials examining drug therapies, medical devices, procedural approaches, and other interventions. Current trial information is available through ClinicalTrials.gov.